medigraphic.com
ISSN 1025-0255 (Electronic)

2017, Number 2

<< Back Next >>

AMC 2017; 21 (2)

Methylation analysis in patients with chronic myeloid leukemia in different medical institutions in Medellín

Patiño ZCY, Jaramillo PLM, Medina GLM, Orozco JLY, Galvéz CKM, Acevedo TPA

Language: Spanish
References: 28
Page: 222-236
PDF size: 964.65 Kb.


ABSTRACT

Background: chronic myeloid leukemia (CML) is a chronic myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome. A specific treatment is designed as tyrosine kinase inhibitors (ITK's), which induces patients to have a hematologic, cytogenetic and molecular response. This disease is characterized by three clinical phases that result from the accumulation of genetic damage, both represented by point mutations and alterations in the karyotype; and epigenetic changes in genes such as ABL, OSCP1, PDLIM4, Npm2, ER and p15.
Objective: to describe the schemes of six gens in patients with chronic myeloid leukemia in different stages of the disease and treated with some ITK in two hospitals in Medellín.
Methods: a descriptive transversal study was conducted, in which 34 samples were collected at the convenience of patients with chronic myeloid leukemia (CML). To make the analysis of these samples methylation specific PCR was done.
Results: statistical differences in blood count data from both phases of the disease was found, a high frequency of methylated genes in accelerated phase was also found. p15 methylation, ABL, ER are independent of the stage of the disease. In patients treated with hydroxyurea, methylation of 100 % for OSCP1 and PDLIM4 genes was observed and this behavior was not observed in individuals treated with ITK'S. In patients who developed resistance to ITK's however was observed a higher percentage of methylation in genes OSCP1 and PDLIM4.
Conclusions: methylation in PDLIM4 and OSCP1 genes could be associated with poor prognosis possibly being associated with progression of chronic to accelerated phase and the development of resistance to ITK's.


REFERENCES

  1. JW_Vardiman JV, Baccarani J MM. Thiele. Chronic myelogenous leukaemia, BCR-ABL1 po-sitive In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tis-sues. Lyon, France: IARC Press; 2001. p. 291-302.

  2. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al, editors. SEER Cancer Statistics Review, 1975-2013 [Internet]. Bethesda: National Cancer Institute; 2016 Apr [cited 2016 May 12]. Available from: http://seer.cancer.gov/csr/1975_2013/.

  3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer Incidence and Mortality. GLOBOCAN [Internet]. 2012 [cited 2016 May 12]1(1):[about 8 p.]. Available from: http://globocan.iarc.fr/old/summary_table_sitehtml.asp?selec-tion=12280&title=Leukaemia&sex=0&type=0&window=1&america=2&sort=3&submit=%C2%A0Execute accessed on 23/05/2016.

  4. Höglund M, Sandin F, Simonsson B. Epide-miology of chronic myeloid leukaemia: an upda-te. Ann Hematol. 2015;94(S2):241–7.

  5. National cancer Institute. Chronic Myeloid Leukemia - SEER Stat Fact Sheets [Internet]. SEER Stat Fact Sheets: chronic Myeloid Leu-kemia (CML); 2016 [citado 2016 May 17]. Avai-lable from: http://seer.cancer.gov/statfacts/html/cmyl.html

  6. Direccion de medicamentos y tecnologias en salud. Actuación admistrativa de la declaratoria de razones de interes público. Medellin: Univer-sidad de Antioquia; 2016.

  7. Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18(4):930–7.

  8. Huu NT, Yoshida H, Yamaguchi M. Overex-pression of tumor suppressor protein OSCP1/NOR1 induces ER stress and apoptosis during development of Drosophila melanogaster. Am J Cancer Res [Internet]. 2015 Jan [2016 citado Feb 29];5(5):[about 11 p.]. Available from: http pmc/articles/PMC4497438/?report=abstract

  9. Asimakopoulos FA, Shteper PJ, Krichevsky S, Fibach E, Polliack A, Rachmilewitz E, et al. ABL1 methylation is a distinct molecular event asso-ciated with clonal evolution of chronic myeloid leukemia. Blood. 1999 Oct 1;94(7):2452-60.

  10. Issa J-PJ, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE, et al. The Estro-gen Receptor CpG Island Is Methylated in Most Hematopoietic Neoplasms. Cancer Res. 1996 Mar 1;56(5):973-7.

  11. Hantschel O, Grebien F, Superti-Furga G. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res. 2012;72(19):4890-5.

  12. Comert M, Baran Y, Saydam G. Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era. Am J Blood Res. 2013 Jan;3(3):191-200.

  13. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhi-bitors of BCR-ABL for the treatment of resistant chronic myeloid leukaemia. Nat Rev Cancer [Internet]. 2007 May [citado 2013 Nov 13];7(5):[about 12 p.]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17457302

  14. Kimura S. [State-of-the-art management of CML in 2015 and future prospects]. Rinsho Ketsueki [Internet]. 2015 Oct [citado 2016 Nov 19];56(10):[about 9 p.]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26458439

  15. Chen S, Sutiman N. Pharmacogenetics of drug transporters in modulating disposition and treatment outcomes in chronic myeloid leu-kemia & gastrointestinal stromal tumor pa-tients. Pharmacogenomics. 2016;17(17):1941-55.

  16. Dietrich D, Lesche R, Tetzner R, Krispin M, Dietrich J, Haedicke W, et al. Analysis of DNA Methylation of Multiple Genes in Microdissected Cells From Formalin-fixed and Paraffin-embedded Tissues. J Histochem Cytochem. 2009;57(5):477-89.

  17. Baccarani M, Castagnetti F, Gugliotta G, Rosti G. A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol [Internet]. abril de 2015 [citado 2016 Apri 1];94 Suppl 2:[about 7 p.]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25814080

  18. Furtado VF, Santos GR, de Carvalho DS, Staziaki PV, Pasquini R, Funke VAM. Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase. Rev Bras Hematol Hemoter. 2015 Ene;37(5):341-7.

  19. Jelinek J, Gharibyan V, Estecio MRH, Kondo K, He R, Chung W, et al. Aberrant DNA methy-lation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One. 2011;6(7):e22110.

  20. Bodoor K, Haddad Y, Alkhateeb A, Al-Abbadi A, Dowairi M, Magableh A, et al. DNA hyper-methylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients. Asian Pa-cific J Cancer Prev. 2014;15(1):75-84.

  21. Gómez Gómez M, Danglot Banck C, Vega Franco L. Sinopsis de pruebas estadísticas no paramétricas. Cúando usarlas. Rev Mex Pedria-tría. 2003;70(2):91-9.

  22. Preisler HD, Li B, Chen H, Fisher L, Nayini J, Raza A, et al. P15 INK4B gene methylation and expression in normal , myelodysplastic , and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients. 2001;1589-95.

  23. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res. 2009 Jun 15;15(12):3927-37.

  24. Jiang D, Hong Q, Shen Y, Xu Y, Zhu H, Li Y, et al. The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis. PLoS One. 2014 Jan;9(5):e96822.

  25. Berrio Carvajal D, Acevedo Toro PA. Fre-cuencia de la mutación T315I y su relación con la resistencia a inhibidores tirosina kinasa en pacientes con leucemia mieloide crónica, en Me-dellín. 2015. Medellin: Universidad de Antio-quia; 2016.

  26. Elias MH, Baba AA, Husin A, Sulong S, Has-san R, Sim GA, et al. HOXA4 gene promoter hy-permethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients. Biomed Res Int. 2013 Jan;2013:129715.

  27. Yang H, Liang H, Yan J, Tao R, Hao S, Ma L. Down-regulation of hematopoiesis master regu-lator PU.1 via aberrant methylation in chronic myeloid leukemia. Int J Hematol [Internet]. 2012 Jul [citado 2013 Oct 25];96(1):[about 9 p.]. Available from: http http://www.ncbi.nlm.nih.gov/pubmed/22674382

  28. Nishioka C, Ikezoe T, Yang J, Udaka K, Yo-koyama A causes epigenetic alterations of PTEN gene via upregulation of DNA methyltransfera-ses and polycomb group proteins. Blood Cancer J. 2011 Dec;1(12):e48.




2020     |     www.medigraphic.com